Eli Lilly vs Pfizer
LLY and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LLY and PFE compare
Eli Lilly is the larger company, worth 8.2 times as much as Pfizer ($1.3T against $165B).
On earnings, Pfizer is cheaper: it trades at 38.0× trailing earnings, against 46.5× for Eli Lilly.
Eli Lilly grew revenue faster over the last twelve months (45.5% versus −0.21% for Pfizer).
Eli Lilly keeps more of each dollar of sales as profit, with a net margin of 31.9% compared with 6.8% at Pfizer.
Both pay dividends: Eli Lilly yields 0.36% and Pfizer 4.5%.
Eli Lilly scores higher on the StockData Score (19 against 9 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LLY | PFE |
|---|---|---|
| Size and price | ||
| Market cap | $1.3T | $165B |
| Share price | $1431.67 | $28.89 |
| Change, 1 year | 40.0% | 11.7% |
| Change, 5 years | 450% | −43.1% |
| Beta (5Y) | 0.26 | – |
| Employees | 50K | 75K |
| StockData Score | ||
| Total score | 19 (better) | 9 |
| Valuation score | 2 (better) | 1 |
| Growth score | 5 (better) | 1 |
| Performance score | 5 (better) | 2 |
| Health score | 4 (better) | 2 |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 46.5× | 38.0× (better) |
| P/S | 15.6× | 2.6× (better) |
| P/B | 33.4× | 1.9× (better) |
| EV/EBITDA | 37.7× | 16.3× (better) |
| P/FCF | – | 15.0× |
| PEG | 0.94 | – |
| FCF yield | – | 6.7% |
| Fair value | $1134.58 | $18.86 |
| Margin of safety | −26.2% (better) | −53.1% |
| Growth | ||
| Revenue growth (TTM) | 45.5% (better) | −0.21% |
| Revenue growth, 5Y average | 21.6% (better) | 8.5% |
| Net income growth (TTM) | 49.8% (better) | −59.7% |
| EPS growth (TTM) | 50.7% (better) | −59.6% |
| EPS growth, 5Y average | 27.6% (better) | −3.6% |
| Profitability | ||
| Gross margin | 83.6% (better) | 73.2% |
| Net margin | 31.9% (better) | 6.8% |
| FCF margin | – | 17.2% |
| Return on equity | 86.1% (better) | 5.0% |
| Financial health | ||
| Debt / equity | 1.23 | 0.74 (better) |
| Net debt / EBITDA | 1.21 (better) | 4.07 |
| Current ratio | 1.39 (better) | 1.27 |
| Altman Z-score | 8.59 (better) | 2.00 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 0.36% | 4.5% (better) |
| Payout ratio | 21.7% | – |
| Years of dividend growth | 9 | 15 (better) |
| Dividend growth, 5Y average | 15.2% (better) | 2.4% |
| Buyback yield | 0.43% | – |
| Shareholder yield | 0.80% | 4.5% (better) |
| Ownership | ||
| Held by institutions | 83.8% | 67.2% |
| Held by insiders | 10.4% | 0.03% |
| Insider net buying, 12 months | −$373M | $2.8M (better) |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 0.86% | 2.4% |
Go deeper
- LLY stock overview
- LLY income statement
- LLY valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.